TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02140008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of I-gel
Description: After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of air-Q
Description: After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
Study: NCT02030717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: klonidin
Description: spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
Study: NCT01111825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 28 day treatment cycle Phase 1~* Weekly intravenously (IV) on days 1, 8, 15, and 22~* Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~* Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~* HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 28 day treatment cycle~• 240 mg orally daily
Study: NCT04618783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
Description: Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
Description: Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
Description: Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three doses of control wIPV, vaccinated within one-month interval between doses
Description: Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three doses of control sIPV, vaccinated within one-month interval between doses
Description: Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
Study: NCT01997632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).
Description: a single 0.5 ml dose Imovax Polio (control vaccine)
Study: NCT01152242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoglycemic Clamp
Description: Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
Study: NCT06046196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate SR
Description: Sarpogrelate SR 300mg, once a daily, for 24weeks
Study: NCT04267029

Intervention type: DIAGNOSTIC_TEST
Intervention: TADPOL battery (deep clinicolaboratory profile)
Description: profile dimensions:~* hemolytic~* allergic~* cardiorenal~* inflammatory~* leukoagglutinating~* exploratory bioarchive

Intervention type: DIAGNOSTIC_TEST
Intervention: TADPOL battery (deep clinicolaboratory profile)
Description: profile dimensions:~* hemolytic~* allergic~* cardiorenal~* inflammatory~* leukoagglutinating~* exploratory bioarchive
Study: NCT04385303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint
Description: One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
Study: NCT06046196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpogrelate
Description: Sarpogrelate 100mg, 3 times a day, for 24weeks
Study: NCT03875066

Intervention type: OTHER
Group type: OTHER
Intervention: Stepping training without feedback
Description: Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.

Intervention type: OTHER
Group type: OTHER
Intervention: Stepping training without feedback
Description: Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
Study: NCT01442688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin + MMX placebo
Description: MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin + MMX mesalazine/mesalamine
Description: MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
Study: NCT04258462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C,15N2-urea
Description: Given IV
Study: NCT03357653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan group
Description: Losartan 50 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 1 pill daily
Study: NCT02030717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural anesthesia
Description: epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
Study: NCT04177953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin AUC 5
Description: chemotherapy iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5
Description: chemotherapy iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 75 mg/m2
Description: chemotherapy iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2
Description: chemotherapy iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed 500 mg/m2
Description: chemotherapy iv
Study: NCT03875066

Intervention type: OTHER
Group type: OTHER
Intervention: Stepping training with feedback
Description: Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
Study: NCT04177953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2
Description: chemotherapy iv

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Human monoclonal antibody
Study: NCT03771638

Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: Open label daily emtricitabine/tenofovir disoproxil oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: Open label daily emtricitabine/tenofovir disoproxil oral tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOT Diary mobile app
Description: DOT Diary mobile application for tracking medication adherence and sexual activities.
Study: NCT01179217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: 0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
Study: NCT01985711

Intervention type: DEVICE
Group type: OTHER
Intervention: web-based collaborative care
Description: Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months.
Study: NCT01985711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: web-based collaborative care
Description: Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: wait-list
Description: Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wait-list
Description: Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual diabetes outpatient care
Study: NCT01152242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoglycemic Clamp
Description: Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: insulin glargine
Description: Insulin glargine at 0.4 U/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: insulin glargine
Description: Insulin glargine at 0.4 U/kg
Study: NCT01985711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual diabetes outpatient care
Study: NCT04489823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVP III
Description: Transcatheter closure of a paravalvular leak using AVP III
Study: NCT02292602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Weight Control
Description: Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
Study: NCT04464369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itopride
Description: itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills matching the look and weight of the itopride tablets
Study: NCT02959853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole
Study: NCT02788019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
Study: NCT01647932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide
Description: hydrochlorothiazide according to clearance of creatinine; \>50ml/min 25mg daily, 20-50ml/min 50mg daily amd \<20ml/min 100mg daily.
Study: NCT03820947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaSeal™ Closure System
Description: The VenaSeal™ closure system is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.

Intervention type: DEVICE
Group type: OTHER
Intervention: VenaSeal™ Closure System
Description: The VenaSeal™ closure system is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endothermal Ablation (ETA)
Description: ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein.~Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Stripping
Description: Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.
Study: NCT03473730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Undergo nephrectomy
Study: NCT00001360

Intervention type: DRUG
Intervention: 0-15 Water
Study: NCT01647932

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo according to clearance of creatinine; \>50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd \<20ml/min 2 pills daily.
Study: NCT02961634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nailner 2 in 1
Description: Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclopirox 8%
Description: Ciclopirox 8% is a glaze used in the treatment of onychomycosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox 8%
Description: Ciclopirox 8% is a glaze used in the treatment of onychomycosis
Study: NCT00993174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical strabismus surgery
Description: Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Tenon's strabismus surgery
Description: Surgery is carried out after sub-Tenon's injection of xylocaine
Study: NCT03094546

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyamine
Description: 12 months of polyamine supplementation (6 capsules/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 months of placebo intake (6 capsules/day)
Study: NCT04090632

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain Upper Extremity Stability Test
Description: Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
Study: NCT01450657

Intervention type: DIETARY_SUPPLEMENT
Intervention: Kibow Biotics/Renadyl
Description: Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 \& 4, three capsules three times daily (270 CFU's). Months 5 \& 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 \& 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
Study: NCT06426966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine is an alkaloid derived from plants native to China called Rhizoma coptidis, Cortex phellodendrine and Hydrastis canadensis. These plants are used in the treatment of infectious diarrhea, inflammation, DM2, non-alcoholic fatty liver disease, dyslipidemias, cardiovascular diseases, and obesity. They have been shown to improve insulin sensitivity and stimulate glucose uptake through the activation of AMP-activated protein kinase (AMPK)
Study: NCT02959853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: weight loss
Study: NCT03309319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: rosiglitazone is added to the primary treatment
Study: NCT01824810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular Stimulation
Description: Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle.
Study: NCT02350790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic ablation
Description: Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic excision
Description: Robotic excision of endometriosis
Study: NCT03553667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard group
Description: Use radial arterial line to monitor mean arterial pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearSight
Description: Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)
Study: NCT03552263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 capsule
Description: T89 capsules (75mg), orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 capsule
Description: T89 capsules (75mg), orally, twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsules (0mg), orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsules (0mg), orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsules (0mg), orally, twice daily.
Study: NCT04255524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optic coherence tomography angiography (OCTA)
Description: Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optic coherence tomography angiography (OCTA)
Description: Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optic coherence tomography angiography (OCTA)
Description: Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optic coherence tomography angiography (OCTA)
Description: Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map
Study: NCT02128178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg 2 hours before arm
Description: Enoxaparin 40 mg 2 hours before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg 2 hours before arm
Description: Enoxaparin 40 mg 2 hours before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg 12 hours before arm
Description: Enoxaparin 40 mg 12 hours before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg 12 hours before arm
Description: Enoxaparin 40 mg 12 hours before surgery